近日,该公司宣布,评估nemolizumab治疗特应性皮炎(AD)相关瘙痒的III期研究结果已发表于国际顶级医学期刊《新英格兰医学杂志》(NEJM)。文章题目为:Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus。 特应性皮炎是一种慢性复发性疾病;其典型症状瘙痒可导致瘙痒-抓挠循环,而瘙痒-抓挠循环...
参考文献: [1]Silverberg J, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 & 2): results from two replicate double-blinded, randomised ...
中重度AD可对患者生活造成不良影响,给患者造成沉重的负担,尤其是搔痒、睡眠剥夺和抑郁。 原文出处:Results of Maruho’s Phase III Study with Chugai’s Nemolizumab for Atopic Dermatitis Published in The New England Journal of Medicine Online 原标题:特应性皮炎(AD)瘙痒新药!新型抗炎药:IL-31受体A靶向阻...
with the HCPLive editorial team, Jonathan Silverberg, MD, PhD, director of clinical research for George Washington University’s School of Medicine and Health Sciences, discussed nemolizumab’s safety profile as well as the phase 3 findings’ wider implications for treatment of atopic...
Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studiesORIENTED ECZEMA MEASURE...
NemolizumabIL-31RαAtopic dermatitisPhase 3 CRSwNP, Chronic rhinosinusitis with nasal polyposis;TSLP, thymic stromal lymphopoietin. Initially, lebrikizumab was studied for the treatment of asthma given the role of IL-13 in mucus hypersecretion,airway remodeling, eosinophil recruitment, and IgE isotype...
In the Phase 3 trials (OLYMPIA 1, OLYMPIA 2) up to 24 weeks, the incidence of treatment-emergent ADAs was 7%; neutralizing antibodies were seen in 3 % of subjects. There was no identified clinically significant effect of anti-drug antibodies on the pharmacokinetics, safety or efficacy of ne...
Silverberg J, et al. Nemolizumab improves skin lesions, itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis: Results from two identical phase 3 multinational studies (ARCADIA 1 and ARCADIA 2). Late-breaking abstract presented at EADV 2023 ...
Silverberg J, et al. Nemolizumab improves skin lesions, itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis: Results from two identical phase 3 multinational studies (ARCADIA 1 and ARCADIA 2). Late-breaking abstract presented at EADV 2023. ...
2.Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus 3.Nemolizumab is associated with a rapid improvement in atopicdermatitissigns and symptomssubpopulation(EASI ≥ 16) analysis of randomized phase 2B study 4.Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis ...